PRODUCTS & INNOVATION
ABBOTT RESPONSE TO THE NYU STUDY
May 13 2020
The NYU study results are not consistent with other studies. For example, in another recent study in Washington state, out of approximately 1,000 subjects there were 23 positive for COVID-19 on a lab test and ID NOW picked up 21, demonstrating 91% sensitivity and 100% specificity. We have many questions for the study authors.
While no test is perfect, Abbott's ID NOW is delivering reliable results when and where they're needed most. The test is performing as expected by the more than 1,000+ sites using ID NOW for COVID-19.
The world needs a variety of tests in labs and at point of care, and as many as possible, if we are to help reduce the risk people have every single day of contracting the virus. ID NOW is an important tool in that equation. Risk reduction is the goal, which is why we're developing as many tests as we can across all of our diagnostics platforms.
An Update on Abbott's Work on COVID-19 Testing
Rapid COVID-19 Test Impacts Generations
Please be aware that the website you have requested is intended for the residents of a particular country or region, as noted on that site. As a result, the site may contain information on pharmaceuticals, medical devices and other products or uses of those products that are not approved in other countries or regions.
The website you have requested also may not be optimized for your specific screen size.
Links which take you out of Abbott worldwide websites are not under the control of Abbott, and Abbott is not responsible for the contents of any such site or any further links from such site. Abbott is providing these links to you only as a convenience, and the inclusion of any link does not imply endorsement of the linked site by Abbott.
The website that you have requested also may not be optimized for your screen size.